N. Rao Movva
Novartis
15 Papers
101 Citations
N. Rao Movva is an academic researcher from Novartis. The author has contributed to research in topics: Saccharomyces cerevisiae & Biology. The author has an hindex of 13, co-authored 15 publications.
Chat about Author
Papers
High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions.
Dominic Hoepfner,Stephen B. Helliwell,Heather Sadlish,Sven Schuierer,Ireos Filipuzzi,Sophie Brachat,Bhupinder Bhullar,Uwe Plikat,Yann Abraham,Marc Altorfer,Thomas Aust,Lukas Baeriswyl,Raffaele Cerino,Lena Chang,David Estoppey,Juerg Eichenberger,Mathias Frederiksen,Nicole Hartmann,Annika Hohendahl,Britta Knapp,Philipp Krastel,Nicolas Melin,Florian Nigsch,Edward J. Oakeley,Virginie Petitjean,Frank Petersen,Ralph Riedl,Esther K. Schmitt,Frank Staedtler,Christian Studer,John A. Tallarico,Stefan Wetzel,Mark C. Fishman,Jeffrey A. Porter,N. Rao Movva +34 more
TL;DR: Using an optimized platform, the relative sensitivities of the heterozygous and homozygous deletion collections for nearly 1800 biologically active compounds are provided, providing unique insights into pathways that are sensitive and resistant to a given perturbation.
168
Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.
Heather Sadlish,Gabriela Galicia-Vázquez,C. Gregory Paris,Thomas Aust,Bhupinder Bhullar,Lena Chang,Stephen B. Helliwell,Dominic Hoepfner,Britta Knapp,Ralph Riedl,Silvio Roggo,Sven Schuierer,Christian Studer,John A. Porco,Jerry Pelletier,N. Rao Movva +15 more
TL;DR: It is demonstrated that the chemically distinct silvestrol and synthetic rocaglamides share a common mechanism of action, which will be critical for optimization of physiologically stable derivatives and confirm the value of the ro caglamide scaffold for exploring the impact of translational modulation on disease.
TORC2 Signaling Pathway Guarantees Genome Stability in the Face of DNA Strand Breaks
Kenji Shimada,Ireos Filipuzzi,Michael Stahl,Stephen B. Helliwell,Christian Studer,Dominic Hoepfner,Andrew Seeber,Andrew Seeber,Robbie Loewith,N. Rao Movva,Susan M. Gasser,Susan M. Gasser +11 more
TL;DR: An inhibitor of target of rapamycin (TOR) complexes 1 and 2 that selectively enhances the sensitivity of sgs1Δ cells to hydroxyurea and camptothecin is identified and implicate TORC2-mediated actin filament regulation in the survival of low levels of DNA damage.
87
The Novolactone Natural Product Disrupts the Allosteric Regulation of Hsp70
A. Quamrul Hassan,Christina A. Kirby,Wenlai Zhou,Tim Schuhmann,Roman Kityk,D. Randal Kipp,Jason Baird,Jinyun Chen,Yaoyu Chen,Franklin Chung,Dominic Hoepfner,N. Rao Movva,Raymond Pagliarini,Frank Petersen,Christopher Quinn,Douglas Frederick Quinn,Ralph Riedl,Esther K. Schmitt,Anne Schitter,Travis Stams,Christian Studer,Pascal D. Fortin,Matthias P. Mayer,Heather Sadlish +23 more
TL;DR: Biochemical and structural analyses indicate that novolactone disrupts interdomain communication by allosterically inducing a conformational change in the Hsp70 protein to block ATP-induced substrate release and inhibit refolding activities, making it a valuable tool for exploring the requirements of HSp70 chaperones in diverse cellular contexts.
56
Identification of elongation factor G as the conserved cellular target of argyrin B.
Beat Nyfeler,Dominic Hoepfner,Deborah Palestrant,Christina A. Kirby,Lewis Whitehead,Robert Yu,Gejing Deng,Ruth E. Caughlan,Angela L. Woods,Adriana K. Jones,S. Whitney Barnes,John R. Walker,Swann Gaulis,Ervan Hauy,Saskia M. Brachmann,Philipp Krastel,Christian Studer,Ralph Riedl,David Estoppey,Thomas Aust,N. Rao Movva,Zuncai Wang,Michael Salcius,Gregory A. Michaud,Gregory McAllister,Leon Murphy,John A. Tallarico,Christine D. Wilson,Charles R. Dean +28 more
TL;DR: It is shown that argyrin B is an antibacterial and cytotoxic agent that inhibits the evolutionarily conserved target EF-G, blocking protein synthesis in bacteria and mitochondrial translation in yeast and mammalian cells.